Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
9.87 HKD +0.61% Intraday chart for Shanghai Junshi Biosciences Co., Ltd. -7.24% -49.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Junshi Bio's 2023 Loss Widens, Misses Estimates MT
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Junshi Biosciences Proposes Share Buyback MT
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA MT
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority CI
Shanghai Junshi Biosciences to Narrow Losses MT
Junshi Bio Inks 40 Million Yuan Deal With Shanghai Allink Biotherapeutics MT
Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023 CI
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer CI
Shanghai Junshi Biosciences Co., Ltd. Announces Change of General Manager CI
Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board CI
Junshi Bio, Coherus Terminate Partnership for TIGIT Antibody MT
Shanghai Junshi Biosciences Co., Ltd. Receives Letter from Coherus Notifying the Company of its Intention to Terminate the Cooperation CI
Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine CI
Junshi Biosciences Secures Supplementary Application Approval for Lung Cancer Therapy in China MT
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023. CI
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients CI
Shanghai Junshi Says New Indications of Two Drugs Added to China’s NRDL MT
China Includes Two Shanghai Junshi Biosciences Drugs in List of Insurance-Backed Drugs MT
Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List CI
Australian Regulator Approves Shanghai Junshi Biosciences' Toripalimab; Shares Down 4% MT
Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA CI
Shanghai Junshi Biosciences Co., Ltd. Has Received A Notice from the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care CI
Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association CI
Shanghai Ruotuo Biotechnology Co., Ltd. announced that it has received equity funding from Shanghai Junshi Biosciences Co., Ltd. and other investors. CI
Chart Shanghai Junshi Biosciences Co., Ltd.
More charts
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company develops innovative drugs and provides clinical research commercialization services worldwide. The Company mainly provides its products in the treatment of tumor immunotherapy, metabolic diseases, inflammation or autoimmune diseases, as well as nervous system diseases. The Company's products are mainly used to treat melanoma, nasopharyngeal cancer, esophageal cancer, urothelial cancer, malignant lymphoma and others. The Company provides its products for domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
9.114 CNY
Average target price
29.04 CNY
Spread / Average Target
+218.63%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Shanghai Junshi Biosciences Co., Ltd. - Hong Kong S.E.
  4. News Shanghai Junshi Biosciences Co., Ltd.
  5. China Approves Supplemental New Drug Application for Junshi Biosciences' Lung Cancer Injectable